Summary Overweight in insulin-dependent diabetes mellitus (IDDM) has been repeatedly reported, especially in girls during adolescence. Potential pathophysiologic factors include tight metabolic control, insulin dose, treatment regimen, puberty and genetics. A standardized data-base from all IDDM patients treated at our institution was evaluated. IDDM patients with hypothyroidism or celiac's disease as well as all records from the first year of diabetes were excluded, resulting in a total of 427 patients (2454 patient-years) available for analysis. BMI and SD-score for BMI based on the Zurich longitudinal growth study were evaluated. Standardized BMI was higher in pubertal children ( + 1.07 ± 0.06) compared to prepubertal children ( + 0.68 ± 0.07; p < 0.002). This increase was present both for boys and girls. Increasing overweight during puberty was found irrespective of the age at diagnosis of diabetes (prepubertal or pubertal). The daily dose of insulin and the long-term metabolic control had only a minor impact on the development of overweight. In contrast, in pubertal children, SDS-BMI was significantly higher in patients on intensified insulin regimens (3 or 4 daily injections) compared to patients with 2 injections (p < 0.05).
These data demonstrate that both boys as well as girls with IDDM develop overweight during puberty. Multiple injection therapy, not daily dose of insulin or the level of metabolic control achieved, was the main predictor of weight gain. This finding may be explained by increased caloric intake due to the flexibility allowed by intensified treatment. [Diabetologia (1998) 
41: 542±547]
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during intensified insulin therapy might lead to increased energy intake in IDDM adolescents. It is of major importance to identify factors related to weight gain in IDDM children and adolescents. Based on a large database from one centre, we therefore investigated the effects of age, gender, insulin dose, injection frequency and metabolic control on body mass index in IDDM patients.
Subjects and methods
Height and weight in IDDM patients were recorded at each visit to our outpatient clinic, using a calibrated stadiometer (mechanical Harpenden stadiometer until 1989, electronic stadiometer Fa Busse, Ulm, Germany, thereafter) and a calibrated gauge. Measurements were documented in a computer system specifically designed for the long-term care of IDDM patients [10] . This program was developed under the auspices of the German Secretary for Health between 1993 and 1995. It is now widely used throughout Germany. The Foxpro databaseformat (Microsoft München, Germany) is utilized for the current version of this programme. Relevant data were extracted from the database using the dBaseV software (Borland Eschborn, Germany).
Body mass index (BMI = weight/(height) 2 ) was used as an index to reflect the height-weight relationship. For each patient, the z-scores (SD-scores) for height, weight and BMI were calculated based on the Zurich longitudinal growth data [11] (normative data for BMI were kindly provided by A. Prader, Zurich). These data have previously been shown to be suitable for children from our region, as demonstrated on a sample of 102 healthy school children [6] and on non-diabetic siblings from patients with diabetes [12] . All measurements from an individual patient within the span of one year were averaged to correct for differences in the number of yearly visits. Therefore, each patient contributed equally to the mean BMI of patients seen within one year. The SAS statistical software package (Carey, N. J., USA) was used for data analysis. As BMI does not necessarily follow a Gaussian distribution in IDDM patients, non-parametrical statistics (Wilcoxon rank-sum test, Spearman coefficient of correlation, multiple regression analysis on ranks) were applied. Statistical evaluation, as well as graphical representation of the data, was performed only for age-groups where at least 30 patients contributed to each subgroup. Data are presented as mean ± standard error (SE), significant differences were assumed for p values of less than 0.05.
Patients were screened yearly for the presence of anti-gliadin IgA-antibodies (ELISA, LD-Labordiagnostika, Heiden, Germany) as well as thyroid antibodies (TAK, TPO; ELISA, Elias, Freiburg, Germany). If gliadin antibodies were positive, the presence of celiac disease was confirmed or excluded by a small bowel biopsy. In all patients with positive thyroid antibodies, thyroid function tests were performed (thyroxine, free thyroxine index, triiodothyronine, thyroxine-stimulating hormone). Hypothyroid patients were excluded from analysis. From August 1992 HbA 1 c was determined every 3 months by HPLC (Micro-Column System, Pharmacia, Freiburg, Germany) (normal range: 4.56 ± 0.55 %). Up to July 1992, ion exchange chromatography was used for HbA 1c measurement (normal range: 4.3 ± 0.5), these values were adjusted to the current method using the SD-score technique [13] .
For a total of 511 patients diagnosed with type-I-diabetes, records including measurements of height and weight as well as information on insulin therapy and metabolic control were available in our database. Prospective longitudinal collection of data started in January 1986, all patients included in the study were seen at our institution between this time-point and December 1996. Additional measurements of height, weight, HbA 1 c and information on insulin therapy, reflecting the course of diabetes between manifestation and December 1985, were extracted from the patient charts. Therefore, in 193 patients (38 % of the total study group), part of the data were collected retrospectively. 84 patients were excluded from analysis for the following reasons: reference data were not applicable because one or both parents were of non-German descent (n = 49), coexistent celiac disease (n = 9), hypothyroidism (n = 11), Down's syndrome (n = 2) or insufficient follow-up period (n = 13). To exclude the effect of weight-loss during initial metabolic decompensation, and the effect of the remission phase with low exogenous insulin requirement, all records related to the first year of diabetes were excluded. Therefore, data encompassing 2454 patientyears from 427 patients (202 boys, 225 girls) were available for analysis. The mean age at diagnosis of diabetes was 8.2 ± 0.2 years, not different between boys (8.2 ± 0.3 years) and girls (8.1 ± 0.3 years).
Results
As depicted in Fig. 1 , BMI in paediatric IDDM patients was higher compared to the reference population even during the prepubertal years. However, following the onset of puberty, BMI increased even further in boys and girls. Standardized BMI-scores allow statistical comparisons between groups. For all 427 subjects, the mean SDS for BMI, weighted with the number of measurements per patient, was + 0.96 ± 0.05 (mean ± SE). The onset of puberty was defined according to chronologic age: 12.2 years in boys (average age at development of pubic hair) and 10.4 years in girls (average onset of breast development) [14, 15] . The weighted mean of BMI-SDS for 355 IDDM children observed during the prepubertal years was + 0.68 ± 0.07, significantly lower compared to + 1.07 ± 0.06 for 222 adolescents observed during the pubertal years (p < 0.002, Wilcoxon sign rank test; Fig. 2 , top panel; 150 patients were observed both during the prepubertal and the pubertal age).
Comparing boys with girls, no significant difference was present for the whole group of 427 patients (males: + 1.02 ± 0.07; females: + 0.89 ± 0.07; NS). In addition, no significant gender difference was encountered for all age-groups with the exception of the age-range 10±13 years, during which interval diabetic boys were significantly more overweight compared with girls (p < 0.01; Fig. 2 , bottom panel). IDDM children were next stratified according to prepubertal or pubertal onset of diabetes. As depicted in Fig. 3 , the increase in BMI was identical for both groups. Statistical comparison revealed no significant difference in standardized BMI for all agegroups between 11 and 25 years. Further subdivision according to gender showed again no difference between boys or girls with prepubertal or pubertal age at diagnosis of diabetes (data not shown). As the definition of pubertal onset was based on chronological age, rather than the recording of Tanner stages, the analysis was repeated for patient subgroups of ªyoung onsetº ( < 10 years at manifestation) and ªold onsetº ( > 13 years). Again, no difference with respect to the development of overweight was present (data not shown).
The development of overweight in diabetic subjects is generally attributed to hyperinsulinisation. Insulin requirement in paediatric IDDM patients is highly dependent on age: on average, reported insulin requirement was 0.67 ± 0.02 U/kg for prepubertal and 0.85 ± 0.01 U/kg for pubertal patients. For each agegroup, therefore the median insulin requirement per kg of body weight was calculated. BMI in subjects with an insulin requirement above or below this limit was compared (see Fig. 4, top panel) . While no difference was present during childhood and early adolescence, in older patients standardized BMI was higher in the subgroup reporting a lower insulin dose per kg of body weight. This difference was significant for patients 17±19 years of age (p < 0.03).
Conventional and intensified insulin treatment can be classified according to the number of daily injections. The treatment regime was dependent on chronological age: At age 11, 59 % of patients injected insulin twice daily, 21 % used 3 and 20 % of patients used 4 injections. The respective numbers were 46 %±27 %±27 % for 14-year-old children and 31 %±31 %±38 % for 17-year-old patients. The number of prepubertal children on 3 or 4 injections was too small for statistical comparison. In pubertal children (12±16 years), standardized BMI was significantly higher for intensified treatment compared with children on a 2 injection regimen (p-values between < 0.04 and < 0.003 for the age-groups respectively; Fig. 4, middle panel) . No difference was present for adult patients ( ³ 17 years).
Metabolic control, as reflected by HbA 1 c , is a further parameter potentially related to weight gain in IDDM subjects. For all patients, the median of all previously measured HbA 1 c -values averaged 7.54 ± 0.22 %. For each age-group, the median long- term HbA 1 c was used as a cutoff between ªgoodº and ªpoorº metabolic control. Patients with ªpoorº longterm metabolic control tended to be more overweight compared with patients with a ªgoodº median HbA 1 c , however this difference was significant only for the age-group 20 years (see Fig. 4 , bottom panel). Multiple regression analysis was utilized to evaluate simultaneously the effects of treatment and metabolic control on the development of overweight. BMI was used as the dependent parameter, and gender, insulin dose per kg of body weight, number of daily injections of insulin and long-term mean HbA 1 c were entered as independent variables into the model. The analysis was performed separately for each yearly interval of chronological age. In children younger than 11 years (n = 130), none of the above factors had a significant impact on BMI. By contrast, in children 12±17 years of age (n = 179±222), the number of daily injections of insulin was the single most important predictor of BMI (p-values < 0.0001 to < 0.005 for the different age groups). Surprisingly, in adults ( ³ 18 years, n = 126), the number of injections per day no longer had a significant influence on BMI. Similar results were obtained when multiple regression analysis was performed on ranks or when BMI-SDS was used as the dependent variable.
Discussion
In contrast to the textbook view that IDDM patients are generally of normal weight, overweight in this group of patients is increasingly recognized and related to intensified insulin treatment and good metabolic control [2, 5] . This phenomenon has also been demonstrated for paediatric patients [12, 16] . In our patient group, the most pronounced elevation of BMI was observed during adolescence, however, even in prepubertal children BMI was increased compared to the control group. In a recent study including nondiabetic siblings from paediatric IDDM patients, we reported a mean BMI-SDS of + 0.28 for these healthy control subjects with the same genetic background [12] . The slightly increased BMI even in young IDDM children might therefore reflect a secular trend in height-weight relationship, or a genetic background of overweight in families with IDDM children. In fact, tall stature and rapid weight gain have been identified as risk-factors for the development of IDDM [17, 18] .
It is a general belief in paediatric diabetology that overweight is more pronounced in IDDM girls compared with boys, a notion which seems to be supported by some studies [19±21] but contradicted by others [22, 23] . Unfortunately, the statistical methods applied in these studies are often insufficient. Based on our large sample of paediatric IDDM patients, followed and documented at our institution, we clearly found that age-and sex-standardized BMI is no higher in girls compared with boys. In contrast, at the onset of puberty, a higher degree of overweight is present in boys, confirming the previous report by Clarson et al. [22] . BMI values objectively reflect the anthropometric aspect of overweight, however, in our society overweight is a more prominent stigma for girls compared with boys, explaining why diabetes care providers are much more exposed to female patients suffering from excessive weight gain.
Several hypotheses have been put forward to explain why overweight is primarily encountered in patients on intensified insulin treatment with good metabolic control: reduced loss of glucose in the urine, increased energy intake due to dietary flexibility with multiple injection regimens, altered basal energy expenditure or the necessity to consume additional carbohydrates due to more frequent hypoglycaemic episodes have been suggested as pathogenetic factors. In a previous study, we examined body composition using bioelectrical impedance measurements in IDDM adolescents [24] . We found that overweight in this group of patients is caused by an increase in muscle mass, while fat mass was similar to age-adjusted control subjects. Peripheral hyperinsulinaemia, in conjunction with elevated growth hormone values and high circulating glucose concentrations, might explain this anabolic effect of diabetes. In diabetic animals, increasing amounts of insulin infused through the physiologic range resulted in a 40 % increase in daily food intake and a rapid gain in body weight [25] . Both hyperinsulinisation as well as intensified insulin treatment have been considered to cause excessive weight-gain in IDDM adolescents. Using multiple regression analysis, we therefore elucidated the contributions of these factors. High insulin dose and good metabolic control had no significant effect on BMI in this age-group. In contrast, multiple injection therapy was strongly associated with high BMI. Intensified conventional therapy with multiple daily insulin injections allows considerable flexibility of dietary habits, this is likely to lead to increased food consumption and subsequent overweight. Our finding, that not tight metabolic control, but the use of multiple injection therapy is the main factor associated with overweight, is clearly in contradiction of the notion that frequent hypoglycaemia and subsequent additional food intake are responsible for overweight. In several studies on intensified insulin regimen, the prevalence of severe hypoglycaemic episodes is inversely correlated to metabolic control [1, 2, 3] , however this point is controversial.
Our results that the number of insulin injections, rather than the total insulin dose, is important for overweight during adolescence may contrast with the general view of many paediatric diabetologists, but is in agreement with several reports in the literature [20, 26] . It is therefore likely that additional food intake made possible by flexible insulin treatment regimens is causing overweight in IDDM adolescents. This pathophysiologic explanation is supported by a recent study from Finland, demonstrating that the daily energy intake in adolescent girls with diabetes is higher compared with control subjects [8] . As patients on two daily injections gain weight as well ± however at a slower pace ±, and as in adults multiple injection therapy is no longer the main factor related to overweight, the other explanations for overweight in IDDM mentioned are likely to contribute as well. It has to be kept in mind that both the insulin doses and the number of daily injections were reported by the patients, and some noncompliance cannot be excluded definitively. The difference between children and adolescents/young adults with IDDM may partly be explained by differences in insulin sensitivity or physical activity between adolescent and adult patients [27, 28] .
Our data do not support the idea that overinsulinisation is a major cause of overweight in adolescent patients. If at all, there was a tendency towards higher BMI in patients using lower doses of insulin per kg of body weight, especially in the older age-groups. However, this finding has to be interpreted with some caution, as only the insulin dose reported by the patients can be evaluated. Skipping insulin shots is frequent among adolescents with diabetes [29] , and is intentionally used by some patients to induce weight loss [30, 9] . The hypothesis that overeating due to frequent hypoglycaemic episodes contributes to weightgain is contradicted by our data: lower HbA 1 c -values ± potentially associated with a higher frequency of severe hypoglycaemic episodes ± are not associated with weight gain [1, 3] . However, recent reports have challenged the view that tight metabolic control is invariably accompanied by a higher frequency of severe hypoglycaemic episodes [31, 32] .
We conclude from our data, that excess caloric intake made possible by multiple injection therapy represents the major factor contributing to overweight in IDDM adolescents. This interpretation is in line with recent psychological studies indicating that classical as well as atypical eating disorders are encountered with a higher frequency especially in female adolescents and young adults with diabetes [33, 34] . Interestingly, body dissatisfaction and unhealthy weightcontrol practices ± which are often unsuccessful ± are prevalent not only among adolescents with diabetes, but also among adolescents with other chronic diseases like asthma, attention deficit disorder, physical disabilities or seizure disorder [35] . As this phenomenon does not seem to be limited to adolescents with nutrition-related chronic illnesses, problems with developmental issues like identity formation, conforming to social norms within the peer group, independence from parents etc. may be the cause of eating disorders and overeating, leading to overweight in chronically ill adolescents.
As overweight has both negative psychological and medical consequences, it remains a major goal of paediatric diabetology to prevent this side-effect of modern therapeutic approaches to IDDM. In our view, the advantages of multiple injection regimen (better metabolic control, increased flexibility) are not to be put into question. However, education related to intensified insulin therapy has to be combined with specific dietary and psychological counselling on the avoidance of weight gain.
